
Please try another search
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Name | Age | Since | Title |
---|---|---|---|
Todd Harris | 46 | 2018 | Co-Founder, President, CEO, Secretary, Treasurer & Director |
Robert J. More | 57 | 2018 | Independent Director |
Rehan Verjee | 44 | 2021 | Independent Director |
Jake Simson | 39 | 2020 | Independent Director |
Melissa McCracken | 38 | 2021 | Independent Director |
Susan Moran | 55 | 2024 | Independent Director |
Jeffrey H. Hager | 60 | - | Scientific Advisor |
Peter G. Smith | - | - | Scientific Advisor |
Adele M. Gulfo | 62 | 2025 | Independent Director |
Jason Sheltzer | - | - | Scientific Advisor |
William C. Hahn | - | - | Scientific Advisor |
S. Michael Rothenberg | 55 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review